Navigation Links
First trial to compare e-cigarettes with nicotine patches
Date:9/7/2013

Barcelona, Spain: First trial to compare e-cigarettes with nicotine patches shows comparable success in helping smokers to quit.

The first ever trial to compare e-cigarettes with nicotine patches has found that both methods result in comparable success in quitting, with roughly similar proportions of smokers who used either method remaining abstinent from smoking for six months after a 13 week course of patches or e-cigarettes.

The study, presented today (8 September 2013) at the European Respiratory Society (ERS) Annual Congress in Barcelona, Spain and published in The Lancet, is only the second controlled trial to be published which evaluates e-cigarettes, and is the first ever trial to assess whether e-cigarettes are more or less effective than an established smoking cessation aid, nicotine patches, in helping smokers to quit.

Led by Associate Professor Chris Bullen, Director of the National Institute for Health Innovation at The University of Auckland in New Zealand, a team of researchers recruited 657 smokers to the trial through adverts in local newspapers. Study participants were all people who wanted to quit smoking, and were divided into three groups: just under 300 (292) received 13 weeks' supply of commercially available e-cigarettes, each of which contained around 16mg nicotine. The same number (292) received 13 weeks' supply of nicotine patches, and a smaller number of participants (73) received placebo e-cigarettes, which contained no nicotine.

Over 13 weeks of using the cessation aids, and 3 months further follow-up, participants underwent testing to establish whether they had managed to remain abstinent from cigarettes. At the end of the six-month study period, around one in twenty study participants (overall, 5.7%) had managed to remain completely abstinent from smoking.

While the proportion of participants who successfully quit was highest in the e-cigarettes group (7.3%, compared to 5.8% for those in the nicotine patches group, and 4.1% in the placebo e-cigarettes group), these differences were not statistically significant. The results suggest that e-cigarettes are comparable to nicotine patches in helping people to quit for at least six months. Additionally, the results found no statistically significant difference in any adverse changes to health reported by participants in the e-cigarettes and the nicotine patches group.

Among those who had not managed to quit after six months, cigarette consumption was markedly reduced in the nicotine e-cigarettes group, compared to the patches and placebo groups; well over half (57%) of the participants in the e-cigarettes group had reduced their daily consumption of cigarettes by at least half after six months, compared to just over two fifths (41%) of the patches group.

In both of the nicotine and placebo e-cigarettes groups, a third of participants were still using the devices after six months, compared to under one in ten (8%) of those in the patches group. When asked whether they would recommend their allocated product to a friend one month after finishing the course, around 9 out of 10 participants in both the e-cigarettes and the placebo groups said they would, compared to just over half (56%) in the patches group; these proportions were little changed after six months.

Professor Bullen said: "Our study establishes a critical benchmark for e-cigarette performance compared to nicotine patches and placebo e-cigarettes, but there is still so much that is unknown about the effectiveness and long-term effects of e-cigarettes. Given the increasing popularity of these devices in many countries, and the accompanying regulatory uncertainty and inconsistency, larger, longer-term trials are urgently needed to establish whether these devices might be able to fulfil their potential as effective and popular smoking cessation aids."

European Respiratory Society President, Professor Francesco Blasi, said: "The introduction of e-cigarettes on the market has caused some debate amongst healthcare professionals. Our position is clear: we need more research on the positive or negative effects of these products.

"This study has taken us one step closer to understanding the effectiveness of these devices as a quitting aid, but we still need long-term independent clinical trials and behavioural studies. It is also essential that research focuses on the safety of these devices, as this is still an area that is lacking data and the results of this study suggest many people are enthusiastic about the use of the devices. Until this strong scientific evidence exists, policymakers who are deciding how to regulate the devices should proceed with caution."


'/>"/>

Contact: Lauren Anderson
lauren.anderson@europeanlung.org
34-693-807-148
European Lung Foundation
Source:Eurekalert

Related medicine news :

1. First targeted nanomedicine to enter human clinical studies
2. First contact: Early intervention key in diagnosis and treatment of serious mental illness
3. Donor Kidney Re-Used in Second Patient After Failing in First
4. Many Who First Misuse Prescription Pills Get Them From Friends, Family: Report
5. First-of-its-kind Menopause Map helps women navigate treatment
6. First recipients of AcademyHealths Presidential Scholarship announced
7. Kessler Foundation researchers present at first International Congress on Cognition in MS
8. Whos the Dad? First-Trimester Blood Test May Tell
9. AGA releases first independently developed ABIM-approved Practice Improvement Module in GI
10. Dr. Yael Mosse will receive first Nachman Award in Pediatric Oncology at national conference
11. First study investigating possible link between sunscreen ingredient and endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... real facts surrounding all those Bible stories. For generations families have gathered to hear ... says there is more to these than just mere “stories”. , The article ...
(Date:2/12/2016)... ... ... of restorative dentistry, to date there has been no other option in the U.S. to ... is a now a new protocol in stopping cavity progression; Silver Diamine Fluoride (SDF). ... The application is as simple as drying the tooth and applying the SDF to ...
(Date:2/11/2016)... ... February 11, 2016 , ... “ HEALING MIND : ... Well Managed Mind” (published by Balboa Press) teaches readers how to become their own ... profound love, author Janice McDermott, M.Ed., LCSW, offers an understanding of how to heal ...
(Date:2/11/2016)... Oregon (PRWEB) , ... February 11, 2016 , ... ... campus participated in the American Osteopathic Association’s (AOA) Match Program Tuesday, February 9, ... Match Program places students into osteopathic graduate medical education positions across the country. ...
(Date:2/11/2016)... ... February 11, 2016 , ... Florida Hospital presents Heart Health Awareness ... St. Louis Blues at the Amalie Arena. The puck drops at 6:00pm, but fans ... the MEGA Heart, prior to the game. The MEGA Heart will be located on ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 2016  NOIT™ Research LLC, a private, leading-edge autism ... campaign to assist needy families in obtaining one of ... between February 10, 2016 and March 31, 2016, the ... The NOIT is an auditory stimulus that plays a ... skills. Beth Shier , NOIT Research ...
(Date:2/11/2016)... Conn. , Feb. 11, 2016  AfterPill.com is ... to recommend alcohol abstinence for all women who are ... in the U.S. each year and raises the risks ... --> --> According to the Guttmacher ... 70% of women of child-bearing age, who have sex ...
(Date:2/11/2016)... Iowa , 11 de fevereiro de 2016 ... inauguração de sua fábrica de soroalbumina bovina (BSA ... Zelândia. A fábrica fica na Ilha Norte da ... "), desenvolvido e estabelecido na fábrica da Proliant ... . O projeto e instalação dos equipamentos ...
Breaking Medicine Technology: